Table 1.

Modelling of HAdV-5 and SARS-CoV-2 coinfection in vitro during simultaneous (A) and consecutive (B) infection of Vero E6 cells (MOI 0.1 TCID₅₀).

(A)
	Monoinfection				Coinfection
	SARS-CoV-2		HAdV-5		SARS-CoV-2 + HAdV-5
Time postinfection	Viral titers, lgTCID50/mL	Viral RNA load according to dPCR, lg genome copies/mL	Viral titers, lgTCID50/mL	Viral DNA load according to dPCR, lg genome copies/mL	Viral titers, SARS-CoV-2/HAdV-5, lgTCID50/mL	Viral RNA/DNA load according to dPCR, SARS-CoV-2/HAdV-5, lg genome copies/mL
24 h	4.7 ± 0.3	7.6 ± 0.4	<1.0	<2.0	4.9 ± 0.3 n/<1.0 n	7.9 ± 0.3 n/<2.0 n
48 h	6.8 ± 0.4	8.8 ± 0.3	3.8 ± 0.3	6.3 ± 0.2	6.7 ± 0.4 n/2.4 ± 0.3 *	8.2 ± 0.3 n/3.8 ± 0.3 *
72 h	5.6 ± 0.3	6.9 ± 0.2	4.8 ± 0.4	6.9 ± 0.3	5.3 ± 0.3 n/2.2 ± 0.2 *	6.5 ± 0.3 n/3.7 ± 0.2 *
(B)
Time Postinfection with SARS-CoV-2	Viral titers (SARS-CoV-2/HAdV-5), lgTCID50/mL		Viral RNA/DNA load according to dPCR (SARS-CoV-2/HAdV-5), lg genome copies/mL		Viral titers (SARS-CoV-2), lgTCID50/mL	Viral RNA load by dPCR (SARS-CoV-2), lg genome copies/mL
	HAdV-5 preinfection-24 h-SARS-CoV-2 infection				Mock preinfection-24 h-SARS-CoV-2 infection
24 h	5.0 ± 0.3 n/2.9 ± 0.2		7.9 ± 0.3 n/5.1 ± 0.2		5.2 ± 0.4	7.7 ± 0.3
48 h	7.1 ± 0.4 n/3.9 ± 0.4		8.9 ± 0.4 n/6.1 ± 0.3		7.0 ± 0.4	8.7 ± 0.4
72 h	5.5 ± 0.3 n/4.7 ± 0.3		7.4 ± 0.3 n/6.2 ± 0.2		5.7 ± 0.3	6.7 ± 0.2
	HAdV-5 preinfection-72 h-SARS-CoV-2 infection				Mock preinfection-72 h-SARS-CoV-2 infection
24 h	5.1 ± 0.3 n/7.2 ± 0.4		7.6 ± 0.2 n/7.9 ± 0.3		5.3 ± 0.3	7.3 ± 0.3
48 h	6.7 ± 0,4 n/7.2 ± 0,4		8.6 ± 0.3 n/8.4 ± 0.4		6.9 ± 0.4	8.8 ± 0.3
72 h	5.2 ± 0.3 n/7.4 ± 0.3		7.2 ± 0.2 n/8.1 ± 0.3		5.3 ± 0.3	7.1 ± 0.2

Values represent means ± SD of three independent experiments. Student’s t-test was used for two-group comparisons. * p < 0.05, ⁿ—not statistically.